Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use

This week, the FDA approved AstraZeneca’s AZN new breast cancer drug, Truqap (capivasertib) and the expanded use of Merck’s MRK blockbuster PD-LI inhibitor, Keytruda in a gastric cancer indication. Novo Nordisk NVO presented updat https://www.nasdaq.com/articles/pharma-stock-roundup:-fda-okays-azns-capivasertib-mrks-keytruda-expanded-use